# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k110780   
B. Purpose for Submission: New device   
C. Measurand: Direct and Total Bilirubin   
D. Type of Test: Quantitative, colorimetric   
E. Applicant: ELITech Group   
F. Proprietary and Established Names: ELITech Clinical Systems Bilirubin Total $4 { + } 1$ ELITech Clinical Systems Bilirubin Direct $4 { + } 1$ ELITech Clinical Systems ELICAL 2 ELITech Clinical Systems ELITROL I and II

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1110: Bilirubin (total or direct) test system 21 CFR 862.1150: Calibrator 21 CFR 862.1660: Quality control material (assayed and unassayed)

2. Classification: Class II, Class II, and Class I reserved, respectively

3. Product code: CIG, JIX, and JJY respectively

4. Panel: 75 Clinical Chemistry

# H. Intended Use:

1. Intended use(s): See indications for use below

2. Indication(s) for use:

ELITech Clinical Systems BILIRUBIN TOTAL $4 { + } 1$ is intended for the quantitative in vitro diagnostic determination of total bilirubin in human serum and plasma on ELITech Clinical Systems Selectra analyzers.

It is not intended for use in Point of Care settings.

Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, are used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder blockage.

ELITech Clinical Systems BILIRUBIN DIRECT $4 { + } 1$ is intended for the quantitative in vitro diagnostic determination of direct bilirubin in human serum and plasma on ELITech Clinical Systems Selectra analyzers.

It is not intended for use in Point of Care settings.

Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, are used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder blockage.

ELITech Clinical Systems ELICAL 2 is a multi-parametric calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems methods on ELITech Clinical Systems Selectra analyzers.

ELITech Clinical Systems ELITROL I & ELITROL II are multi-parametric control sera for in vitro diagnostic use in the quality control of quantitative ELITech Clinical Systems methods on ELITech Clinical Systems Selectra analyzers.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements:

ELITech Clinical Systems Selectra Pro M analyzer

# I. Device Description:

ELITech Clinical Systems BILIRUBIN TOTAL $4 { + } 1$ is available as kit only. It consists of 2 reagents, “R1” and “R2”. Reagent R1 contains sulfanilic acid, Hydrochloric acid and cetrimide. Reagent R2 contains sodium nitrite.

ELITech Clinical Systems BILIRUBIN DIRECT $4 { + } 1$ is available as kit only. It consists of 2 reagents, “R1” and “R2”. Reagent R1 contains sulfanilic acid and Hydrochloric acid. Reagent R2 contains sodium nitrite.

ELITech Clinical Systems ELICAL 2 is a lyophilized calibrator based on human serum containing constituents to ensure optimal calibration. ELITech Clinical Systems ELITROL I and ELITROL II are two level quality control products consisting of lyophilized human serum containing constituents at desired levels.

ELICAL 2, Elitrol I and Elitrol II are prepared exclusively from the blood of donors tested individually and found to be negative for HbsAg and to antibodies to HCV and HIV by FDA-approved methods or similar methods.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

ABX PENTRA BILIRUBIN, TOTAL CP ABX PENTRA BILIRUBIN, DIRECT CP Roche Diagnostics Calibrator for Automated Systems (C.f.a.s) Roche Diagnostics Precinorm U and Precipath U

2. Predicate 510(k) number(s):

k060325 – Total and Direct Bilirubin   
k033501 – Calibrator   
k041227 – Controls

3. Comparison with predicate:

# ELITech Clinical Systems BILIRUBIN TOTAL $4 { + } 1$

<table><tr><td></td><td>Similarities and Differences</td><td></td></tr><tr><td>Item</td><td>ELITech Clinical Systems BILIRUBIN TOTAL 4+1 (Candidate device)</td><td>ABX PENTRA BILIRUBIN, TOTAL CP (Predicate device)</td></tr><tr><td>Intended use</td><td>For quantitative in vitro diagnostic determination of</td><td>Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">total bilirubin in human serumand plasma</td><td colspan="1" rowspan="1">Y</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">Measurements of the levels ofbilirubin, an organiccompound formed during thenormal and abnormaldestruction of red blood cells,are used in the diagnosis andtreatment of liver, hemolytichematological, and metabolicdisorders, including hepatitisand gall bladder block</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Malloy-Evelyn modifiedmethod</td><td colspan="1" rowspan="1">Photometric test using 2,4-dichloroaniline (DCA) and aspecific mixture of detergents</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Reagent 1 :Sulfanilic acid 29 mmol/LHydrochloric acid 67 mmol/LCetrimide 37 mmol/LReagent 2 :Sodium nitrite 5.8 mmol/L</td><td colspan="1" rowspan="1">Reagent 1 :Phosphate buffer 50 mmol/LNaCi 150 mmol/LDetergents , StabilizersReagent 2 :2,4-Dichlorophenyl diazonium salt 5 mmol/LHCl 130 mmol/LDetergent</td></tr><tr><td colspan="1" rowspan="1">Appearance ofreagent</td><td colspan="1" rowspan="1">Liquid form, ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum, Lithium heparinplasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent storage</td><td colspan="1" rowspan="1">Store at 2-8 °C and protectfrom light. The reagent isstable until the expiry datestated on the label.</td><td colspan="1" rowspan="1">Reagents, in unopened cassette,are stable up to expiry date onthe label if stored at 2-8°C andcontamination is avoided.</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Adults : 0.3 - 1.2 mg/dL</td><td colspan="1" rowspan="1">Adults : 0.1  1.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Selectra ProM</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">0.28 to 20.22 mg/dL</td><td colspan="1" rowspan="1">0.2 to 26.3 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit of detection(LoD)</td><td colspan="1" rowspan="1">0.06 mg/dL</td><td colspan="1" rowspan="1">0.09 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofquantification(LoQ)</td><td colspan="1" rowspan="1">0.17 mg/dL</td><td colspan="1" rowspan="1">0.14 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within runLevel 1.04 mg/dL CV=2.7%Level 3.67 mg/dL CV=0.8%Level 14.90 mg/dL CV=0.5%TotalLevel 1.04 mg/dL CV=4.0%</td><td colspan="1" rowspan="1">Within runLevel 0.97 mg/dL CV=2.14%Level 5.13 mg/dL CV=0.99%Level 0.61 mg/dL CV=3.09%Level 0.85 mg/dL CV=2.23%Level 2.20 mg/dL CV=1.33%</td></tr></table>

ELITech Clinical Systems BILIRUBIN DIRECT $4 { + } 1$   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 3.67 mg/dL CV=2.0%Level 14.90 mg/dL CV=1.8%</td><td rowspan=1 colspan=1>Level 8.35 mg/dL CV=0.83%TotalLevel 1.0 mg/dL CV=4.04%Level 5.5 mg/dL CV=1.70%Level 0.8 mg/dL CV=5.97%Level 2.9 mg/dL CV=2.78%Level 9.1 mg/dL CV=2.20%</td></tr><tr><td rowspan=1 colspan=1>Method comparison</td><td rowspan=1 colspan=1>y=0.924x + 0.02 mg/dLr2= 0.998range: 0.30 to 20.22 mg/dL</td><td rowspan=1 colspan=1>y=1.03x - 0.14 mg/dLr2= 0.9965range: 0.3 to 25.8 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>Triglycerides: No significantinterference up to 2779 mg/dLHemoglobin: No significantinterference up to 500 mg/dL.Acetaminophen: Nosignificant interference up to30 mg/dL.Ascorbic acid: Concentration&gt;2.0 mg/dL will interfere andcause erroneous results.Acetylsalicylic acid: Nosignificant interference up to200 mg/dL</td><td rowspan=1 colspan=1>Hemoglobin: No significantinfluence is observed up to 500mg/dL.Triglycerides: No significantinfluence is observed up to612.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>CalibrationFrequency</td><td rowspan=1 colspan=1>28 days</td><td rowspan=1 colspan=1>10 days</td></tr><tr><td rowspan=1 colspan=1>On board stability</td><td rowspan=1 colspan=1>refrigerated area : 28 days</td><td rowspan=1 colspan=1>refrigerated area: 25 days</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Recommended calibrationmaterial (not included):ELITech Clinical SystemsELICAL 2</td><td rowspan=1 colspan=1>Recommended calibrationmaterial (not included): ABXPentra Multical</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Recommended quality controlmaterial (not included):ELITech Clinical SystemsELITROL I (Normal control)ELITech Clinical SystemsELITROL II (Pathologiccontrol)</td><td rowspan=1 colspan=1>Recommended quality controlmaterial (not included):ABX Pentra N Control (Normalcontrol)ABX Pentra P Control(Pathologic control)</td></tr></table>

<table><tr><td></td><td>Similarities and Differences</td><td></td></tr><tr><td>Item</td><td>ELITech Clinical Systems BILIRUBIN DIRECT 4+1 (Candidate device)</td><td>ABX PENTRA BILIRUBIN, DIRECT CP (Predicate device)</td></tr><tr><td>Intended use</td><td>For the quantitative in vitro diagnostic determination of</td><td>Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">direct bilirubin in humanserum and plasma</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">Measurements of the levels ofbilirubin, an organiccompound formed during thenormal and abnormaldestruction of red blood cells,are used in the diagnosis andtreatment of liver, hemolytichematological, and metabolicdisorders, including hepatitisand gall bladder block</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Malloy-Evelyn modifiedmethod</td><td colspan="1" rowspan="1">Photometric test using 2,4-dichloroaniline (DCA)</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Reagent 1 :Sulfanilic acid 29 mmol/LHydrochloric acid 67 mmol/LReagent 2 :Sodium nitrite 5.8 mmol/L</td><td colspan="1" rowspan="1">Reagent 1 :Sulfamic acid 100 mmol/LEDTA-Na 2 0.1 mmol/LNaCl. 150 mmol/LReagent 2 :2,4-Dichlorophenyldiazonium salt 0.5 mmol/LHC1 900 mmol/LEDTA-Na2 0.13 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Appearance ofreagent</td><td colspan="1" rowspan="1">Liquid form, ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum, Lithium heparinplasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent storage</td><td colspan="1" rowspan="1">Store at 2-8 °C and protectfrom light. The reagent isstable until the expiry datestated on the label.</td><td colspan="1" rowspan="1">Reagents, in unopened cassette,are stable up to expiry date onthe label if stored at 2-8°C andcontamination is avoided.</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">&lt; 0.2 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Selectra ProM</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">0.18 to 6.82 mg/dL</td><td colspan="1" rowspan="1">0.09 to 6.71 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit of detection(LoD)</td><td colspan="1" rowspan="1">0.06 mg/dL</td><td colspan="1" rowspan="1">0.04 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limit ofquantification(LoQ)</td><td colspan="1" rowspan="1">0.17 mg/dL</td><td colspan="1" rowspan="1">0.04 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within runLevel 0.49 mg/dL CV=2.0%Level 1.89 mg/dL CV=0.6%Level 4.96 mg/dL CV=0.5%TotalLevel 0.49 mg/dL CV=4.7%Level 1.89 mg/dL CV=3.3%</td><td colspan="1" rowspan="1">Within runLevel 0.90 mg/dL CV=0.67%Level 1.85 mg/dL CV=0.44%Level 0.23 mg/dL CV=3.23%Level 1.52 mg/dL CV=0.59%Level 7.88 mg/dL CV=2.69%Total</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Level 4.96 mg/dL CV=3.2%</td><td colspan="1" rowspan="1">Level 0.94 mg/dL CV=4.26%Level 2.02 mg/dL CV=4.22%Level 0.69 mg/dL CV=3.27%Level 3.83 mg/dL CV=2.98%</td></tr><tr><td colspan="1" rowspan="1">Method comparison</td><td colspan="1" rowspan="1">y=0.988x + 0.07 mg/dLr2= 0.974range: 0.25 to 6.55 mg/dL</td><td colspan="1" rowspan="1">y=1.06x + 0.04 mg/dLr2= 0.9928range: 0.09 to 6.71 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Limitations</td><td colspan="1" rowspan="1">Triglycerides: No significantinterference up to 2106 mg/dLHemoglobin:No significant interference upto 125 mg/dL.Acetaminophen: Nosignificant interference up to30 mg/dL.Ascorbic acid: Concentration&gt;0.3 mg/dL will interfere andcause erroneous results.Acetylsalicylic acid:No significant interference upto 200 mg/dL</td><td colspan="1" rowspan="1">Hemoglobin: do not usehemolyzed samplesTriglycerides: No significantinfluence is observed up to612.5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">CalibrationFrequency</td><td colspan="1" rowspan="1">28 days</td><td colspan="1" rowspan="1">10 days</td></tr><tr><td colspan="1" rowspan="1">On board stability</td><td colspan="1" rowspan="1">refrigerated area : 28 days</td><td colspan="1" rowspan="1">refrigerated area: 30 days</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Recommended calibrationmaterial (not included):ELITech Clinical SystemsELICAL 2</td><td colspan="1" rowspan="1">Recommended calibrationmaterial (not included):ABX Pentra Multical</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ELITech Clinical SystemsELITROL I (Normal control)ELITech Clinical SystemsELITROL II (Pathologiccontrol)</td><td colspan="1" rowspan="1">Recommended quality controlmaterial (not included):ABX Pentra N Control(Normal control)ABX Pentra P Control(Pathologic control)</td></tr></table>

ELITech Clinical Systems Elical 2   

<table><tr><td colspan="3" rowspan="1">Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">ELITech Clinical SystemsElical 2 (Candidate device)</td><td colspan="1" rowspan="1">Roche Calibrator (C.f.a.s)k033501 (Predicate device)</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationsfor Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use inthe calibration of quantitativemethods</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Lyophilized calibrator basedon human serum withconstituents added as required</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">to obtain desired componentlevels</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Level</td><td colspan="1" rowspan="1">Single level</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">Lyophilized: store at 2-8° Cand protect from light until theexpiry date.After reconstitution: For totalbilirubin: 6 hrs. at 15-25° C, 1day at 2-8° C, 2 weeks at -15°C and -25° C. For directbilirubin: 3 hrs. at 15-25° C, 8hrs. at 2-8° C, 2 weeks at -15°C and -25° C.</td><td colspan="1" rowspan="1">Same</td></tr></table>

# ELITech Clinical Systems Elitrol I and II

<table><tr><td rowspan=1 colspan=3>Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>ELITech Clinical SystemsElitrol I/Elitrol II (Candidatedevice)</td><td rowspan=1 colspan=1>Roche Diagnostics PrecinormU and Precipath U (k041227)(Predicate device)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationsfor Use</td><td rowspan=1 colspan=1>For in vitro diagnostic use inquality control of quantitativemethods</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized calibrator basedon human serum withconstituents added as requiredto obtain desired componentlevels</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Two levels</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Lyophilized: store at 2-8° Cand protect from light until theexpiry date.After reconstitution: For totalbilirubin: 8 hrs. at 15-25° C, 1day at 2-8° C, 2 weeks at -15°C and -25° C. For directbilirubin: 4hrs. at 15-25° C, 8hrs. at 2-8° C, 2 weeks at -15°C and -25° C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP07-A2 Interference Testing in Clinical Chemistry; Approved Guideline, Second Edition

CLSI EP09-A2 Method comparison and Bias estimation using patient samples;

Approved guideline, Second Edition

CLSI EP06-A Evaluation of the linearity of the measurement of quantitative procedures: a statistical approach

CLSI EP05-A2 Evaluation of precision performance of quantitative measurement methods; Approved guideline – Second Edition

CLSI EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

FR EN 13640:2002 Stability Testing of in vitro Diagnostic Reagents

“Code of Federal Regulations , Title 21, Volume 8, Part 807 –Establishment registration and device listing for manufacturers and initial importers of devices , revised as of April 1, 2008, 21CFR807”

“Abbreviated 510(k) submissions for In Vitro Diagnostic Calibrators, Feb 1999”

“Assayed and Unassayed Quality Control Material: Guidance for Industry and FDA Staff, June 2007.”

# L. Test Principle:

ELITech Clinical Systems BILIRUBIN TOTAL $4 { + } 1$

In the presence of cetrimide, conjugated and unconjugated bilirubin react with diazotized sulfanilic acid to form azobilirubin. Determination of total bilirubin according to the following reactions:

Sulfanilic acid reacts with NaNO2 to form Diazotized sulfanilic acid; Bilirubin then reacts with Diazotized sulfanilic acid to form Azobilirubin

# ELITech Clinical Systems BILIRUBIN DIRECT $4 { + } 1$

In the absence of cetrimide, only conjugated bilirubin reacts with diazotized sulfanilic acid to form azobilirubin. Determination of direct bilirubin according to the following reactions:

Sulfanilic acid reacts with NaNO2 to form Diazotized sulfanilic acid; Conjugated bilirubin then reacts with Diazotized sulfanilic acid to form Azobi

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision was evaluated with one serum control material, one natural human serum sample, and one spiked human serum pool sample. Within-run and total precision results were obtained by performing two runs per day, two measures per run, for twenty days according to CLSI protocol EP5-A2 using two Selectra Pro M instruments. The results are presented in the tables below:

For total bilirubin precision results:

<table><tr><td rowspan=1 colspan=1>Testlevels</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>Within-run CV (%)</td><td rowspan=1 colspan=1>Total CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>2.7 %</td><td rowspan=1 colspan=1>4.0 %</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.67</td><td rowspan=1 colspan=1>0.8 %</td><td rowspan=1 colspan=1>2.0 %</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>14.90</td><td rowspan=1 colspan=1>0.5 %</td><td rowspan=1 colspan=1>1.8 %</td></tr></table>

For direct bilirubin precision results:

<table><tr><td rowspan=1 colspan=1>Testlevels</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>Within-run CV (%)</td><td rowspan=1 colspan=1>Total CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>2.0 %</td><td rowspan=1 colspan=1>4.7 %</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.89</td><td rowspan=1 colspan=1>0.6 %</td><td rowspan=1 colspan=1>3.3 %</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.96</td><td rowspan=1 colspan=1>0.5 %</td><td rowspan=1 colspan=1>3.2 %</td></tr></table>

# b. Linearity/assay reportable range:

For total bilirubin assay:

A linearity study of the total bilirubin assay was performed according to the CLSI EP6-A guideline. Two pools of patient serum samples were prepared to obtain one high and one low concentration of serum pools. A high sample was obtained by spiking the serum pool to obtain a high concentration of a sample pool $2 0 . 2 2 \mathrm { m g / d L } )$ ). A low sample pool was prepared by diluting a low sample pool with buffered saline to obtain a low concentration of a sample pool $( 0 . 2 8 \mathrm { m g / d L } )$ . Using the high and low pooled samples, eleven levels of inter-mixtures were prepared according to the CLSI EP6-A guideline. All samples were assayed in triplicate. Data was analyzed using $1 ^ { \mathrm { s t } }$ , $\bar { 2 } ^ { \mathrm { n d } }$ , and $3 ^ { \mathrm { r d } }$ order least square regressions. A first order linear regression was generated as follows:

$$
\mathrm { Y = 1 } . 0 0 7 4 \mathrm { X } - 0 . 0 4 , \mathrm { r } = 0 . 9 9 9 7
$$

The results of the study support the sponsor’s claim that the total bilirubin assay has a measuring range of 0.28 to $2 0 . 2 2 \mathrm { m g / d L }$ .

Dilution study:

The sponsor performed a 1:5 manual dilution study with 10 spiked samples using saline as the diluent. Ten samples with total bilirubin concentrations between 16.5 to $9 8 . 9 \mathrm { m g / d L }$ were diluted 1:5. The $\%$ recovery between the expected values and observed values are within $10 \%$ . Therefore, the sponsor claimed that sample with total bilirubin concentration greater than the upper claimed measuring range $( 2 0 . 2 2 \mathrm { m g / d L } )$ can be diluted manually 1:5 with saline.

For direct bilirubin assay:

A linearity study of the direct bilirubin assay was performed according to the CLSI EP6-A guideline. Two pools of patient serum samples were prepared to obtain one high and one low concentration of serum pools. A high sample was obtained by spiking the serum pool to obtain a high concentration of a sample pool $( 6 . 8 2 \mathrm { m g / d L } )$ ). A low sample pool was prepared by diluting a low sample pool with buffered saline to obtain a low concentration of a sample pool $\mathrm { 0 . 1 8 \ m g / d L } )$ . Using the high and low pooled samples, eleven levels of inter-mixtures were prepared according to the CLSI EP6-A guideline. All samples were assayed in triplicate. Data was analyzed using 1st, 2nd, and 3rd order least square regressions. A first order linear regression was generated as follows:

Y=1.0293X - 0.0259, $\mathbf { r } = 0 . 9 9 9 2$

The results of the study support the sponsor’s claim that the total bilirubin assay has a measuring range of 0.18 to $6 . 8 2 \mathrm { m g / d L }$ .

Dilution study:

The sponsor performed a 1:5 manual dilution study with 10 spiked samples using saline as the diluent. Ten samples with direct bilirubin concentrations between 5.4 to $3 2 . 3 ~ \mathrm { m g / d L }$ were diluted 1:5. The $\%$ recovery between the expected values and observed values are within $10 \%$ . Therefore, the sponsor claimed that sample with direct bilirubin concentration greater than the upper claimed measuring range $\mathrm { 6 . 8 2 \ m g / d L } )$ can be diluted manually 1:5 with saline.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

ELICAL 2 calibrator for total bilirubin and direct bilirubin is purchased from a commercially available source and relabeled (previously cleared in k033501) and is traceable to a NIST traceable material, SRM 916a.

ELICAL 2 calibrator is value assigned using multiple runs on two Selectra Pro M analyzers. The target value of ELICAL 2 calibrator is the mean of the observed values range. After validation of the target value, a confidence range (high and low values) is calculated. On-board calibration stability is 28 days for both total and direct bilirubin assays. Reconstituted calibrator stability for both analytes has been verified for the following temperatures and time limits. For total bilirubin: 6 hrs. at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ , 1 day at $2 { - } 8 ^ { \circ } \mathrm { C }$ , 2 weeks at $- 1 5 ^ { \circ } \mathrm { C }$ and - $2 5 ^ { \circ } \mathrm { C }$ . For direct bilirubin: 3 hrs. at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ , 8 hrs. at $2 { - } 8 ^ { \circ } \mathrm { C }$ , 2 weeks at - $1 5 ^ { \circ } \mathrm { C }$ and $- 2 5 ^ { \circ } \mathrm { C }$ .

Control material was purchased from commercially available sources and relabeled (previously cleared in k041227). ELITROL I and II control solutions are value assigned using two Selectra Pro M analyzers. Each sample is tested in triplicate over several days. The target value of Level I and $\mathrm { I I }$ are the median of the observed values range. After validation of the target value, a confidence range (high and low values) is calculated. Reconstituted control stability for both analytes has been verified for the following temperatures and time limits. For total bilirubin: 8 hrs. at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ , 1 day at $2 { - } 8 ^ { \circ } \mathrm { C }$ , 2 weeks at $. 1 5 ^ { \circ } \mathrm { C }$ and $- 2 5 ^ { \circ } \mathrm { C }$ . For direct bilirubin: 4hrs. at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ , 8 hrs. at $2 { - } 8 ^ { \circ } \mathrm { C }$ , 2 weeks at $- 1 5 ^ { \circ } \mathrm { C }$ and $- 2 5 ^ { \circ } \mathrm { C }$ .

Reagent stability for the total bilirubin and direct bilirubin were evaluated on one Selectra analyzer with one lot of reagent using 4 controls and a linearity set for each measurand. Real-time stability study of the reagents supports shelf-life claims of 18 months when stored at 2 to $8 ^ { \circ } \mathrm { C }$ . On board stability are 28 days for total and direct bilirubin. Protocol and acceptance criteria are found to be acceptable.

# d. Detection limit:

The Limits of Blank (LoB), Detection (LoD) and Quantitation (LoQ) studies were conducted following CLSI EP17-A for total bilirubin and direct bilirubin. Two Selectra Pro M analyzers and two lots of the respective reagents were used. The LoBs were determined by analyzing a blank sample 60 times. The LoD and LoQ studies each used 4 serum pools (each measured 15 times) for the individual assays with a total of 60 measurements. The serum pools for the LoD had concentrations of the individual measurand approximately 4 times the LoB. LoQs were determined by analyzing 4 serum pools near the expected LoQ. Results are summarized below:

<table><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>Total bilirubin</td><td rowspan=1 colspan=1>0.04 mg/dL</td><td rowspan=1 colspan=1>0.06 mg/dL</td><td rowspan=1 colspan=1>0.17 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Direct bilirubin</td><td rowspan=1 colspan=1>0.04 mg/dL</td><td rowspan=1 colspan=1>0.06 mg/dL</td><td rowspan=1 colspan=1>0.17 mg/dL</td></tr></table>

The total bilirubin assay has a measuring range of 0.28 to $2 0 . 2 2 \mathrm { m g / d L }$ .

The direct bilirubin assay has a measuring range of 0.18 to $6 . 8 2 \mathrm { m g / d L }$ .

# e. Analytical specificity:

Testing for interfering substances was based on CLSI EP-7A for both total bilirubin and direct bilirubin assay. Testing was performed on various different concentrations for each interfering substances. Samples with increasing amounts of triglycerides, hemoglobin, acetaminophen, acetylsalicylic, and ascorbic acid were tested in triplicate and compared to the same sample without the interfering substances. The sponsor defined nonsignificant interference as the highest level tested that does not cause ${ > } 1 0 \%$ change between the tested samples and the control sample. Results are summarized in the tables below:

For total bilirubin assay: Two levels of analytes concentrations were tested (1.0 and $1 5 . 0 \ : \mathrm { m g / d L }$ )

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Highest concentration testedshowing non-significantinterference(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>2779</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>2.0</td></tr></table>

For direct bilirubin assay: Two levels of analytes concentrations were tested (0.5 and $4 . 5 \mathrm { m g / d L } )$ )

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Highest concentration testedshowing non-significantinterference(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>2106</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>0.3</td></tr></table>

Based on the interference study data, the sponsor has the following limitations in the labeling:

For total bilirubin assay:

Ascorbic acid concentrations greater than $2 . 0 \mathrm { m g / d L }$ cause falsely elevated total bilirubin results.

For direct bilirubin assay:

Ascorbic acid concentrations greater than $0 . 3 \mathrm { m g / d L }$ cause falsely elevated total bilirubin results.

Specimen requirement: Serum, free of hemolysis.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

For total bilirubin assay:

A method comparison study was performed using the Elitech total bilirubin reagent (on Selectra Pro M analyzer) and the Horiba ABX bilirubin total CP reagent (on Pentra 400 analyzer). A total of 100 serum samples were used, including 4 diluted samples. The sample range tested was 0.30 to 20.22 $\mathrm { m g / d L }$ . Result of the linear regression analysis is shown in the table below:

<table><tr><td rowspan=1 colspan=1>Slope (95%CI)</td><td rowspan=1 colspan=1>Intercept (95%CI)</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>0.924(0.918 to 0.929)</td><td rowspan=1 colspan=1>0.02 (-0.01 to 0.06)</td><td rowspan=1 colspan=1>0.998</td></tr></table>

For direct bilirubin assay:

A method comparison study was performed using the Elitech direct bilirubin reagent (on Selectra Pro M analyzer) and the Horiba ABX bilirubin direct CP reagent (on Pentra 400 analyzer). A total of 100 serum samples were used, including 10 diluted samples. The sample range tested was 0.25 to 6.55 $\mathrm { m g / d L }$ . Result of the linear regression analysis is shown in the table below:

<table><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>Intercept (95%CI)</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>0.988(0.965 to 1.011)</td><td rowspan=1 colspan=1>0.07 (0.01 to 0.14)</td><td rowspan=1 colspan=1>0.974</td></tr></table>

b. Matrix comparison:

For total bilirubin assay:

A matrix comparison study with 45 paired serum and plasma (lithium heparin) samples were performed using one Selectra Pro M analyzer. 4 out of the 45 samples were spiked. Sample range tested was 0.35 to $1 8 . 6 6 \mathrm { m g / d L }$ . Result of the linear regression analysis is shown in the table below:

<table><tr><td rowspan=1 colspan=1>Slope (95%CI)</td><td rowspan=1 colspan=1>Intercept (95%CI)</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>1.023(1.008 to 1.039)</td><td rowspan=1 colspan=1>-0.06 (-0.18 to 0.06)</td><td rowspan=1 colspan=1>0.995</td></tr></table>

For direct bilirubin assay:

A matrix comparison study with 40 paired serum and plasma (lithium heparin) samples were performed using one Selectra Pro M analyzer. 4 out of the 40 samples were spiked. Sample range tested was 0.20 to $5 . 8 4 \mathrm { m g / d L }$ . Result of the linear regression analysis is shown in the table below:

<table><tr><td rowspan=1 colspan=1>Slope(95%CI)</td><td rowspan=1 colspan=1>Intercept (95%CI)</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>0.953(0.920 to 0.987)</td><td rowspan=1 colspan=1>0.05 (-0.06 to 0.16)</td><td rowspan=1 colspan=1>0.978</td></tr></table>

Based on the data, the sponsor claims that the lithium heparin is an acceptable anticoagulant for both assays.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

Reference range is cited from the literature:   
For total bilirubin: Serum, plasma: Adults: 0.3 to $1 . 2 \mathrm { m g / d L }$   
Tietz, N.W. Clinical guide to laboratory test, $3 ^ { \mathrm { r d } }$ Ed, (W.B. Saunders eds,, Philadephia USA), 1995. For direct bilirubin: Serum, plasma: Adults: ${ < } 0 . 2 \ \mathrm { m g / d L }$   
Sherwin, J.E., Thompson, C., Liver function. Clinical Chemistry: Theory, Analysis, Correlation, $\dot { \boldsymbol { 4 } } ^ { \mathrm { t h } }$ ed.,and Kaplan, L.A., A.J., Kazmierczak, S.C., (Mosby Inc. eds, St. Louis USA), 2003, 493 and appendix.

It is recommended for each laboratory to establish and maintain its own reference values. The values given are used as guidelines only.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.